Top health-care stocks:
Health-care shares were mainly higher in pre-market trade Thursday.
In health-care stock news, Eli Lilly ( LLY ) and Merck ( MRK ) Thursday reported an extension of a collaboration on safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal phase 3 study in first-line nonsquamous non-small cell lung cancer (NSCLC). Eli Lilly stock shares were flat in pre-market trading , and closed at $83.65 yesterday, in the top half of the 52-week range of $66.56 - $92.85. Merck shares were up 1% in pre-bell at $54.23, within the 52-week range of $45.69 - $63.62
Athersys ( ATHX ) Thursday reported that that multi-potent adult progenitor cells used in Athersys cell therapy currently in clinical development, are effective in improving the health of rodents after acute spinal cord injury. Shares, flat in pre-bell, closed at $1.01 yesterday, on the bottom of the 52-week range of $0.90 - $3.43 per unit.
AMAG Pharmaceuticals ( AMAG ) fell in pre-market trading after the U.S. Food and Drug Administration said the company's single-dose vial of Makena cannot be approved in its current form. In a complete response letter the FDA requested more information on Makena, a drug to reduce the risk of preterm birth in certain at-risk patients. Shares of AMAG fell 11% in pre-bell trading to a 52-week low of $25.87. The stock's 52-week range before today was $27.44 - $77.73.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.